title: Lamotrigine monotherapy for newly diagnosed typical absence seizures in children.
abstract: OBJECTIVE
  To evaluate the efficacy, tolerability, and effects on behavior and psychosocial functioning of lamotrigine monotherapy in children with newly diagnosed typical absence seizures.
  
  
  METHODS
  Children meeting enrollment criteria (n=54) received a confirmatory 24-h ambulatory electroencephalogram (EEG) and then entered a Escalation Phase of up to 20-weeks during which lamotrigine was titrated until seizures were controlled or maximum dose (10.2mg/kg) was reached. Seizure freedom was assessed by diary review and clinic hyperventilation (clinic HV) and then confirmed by EEG with hyperventilation (HV/EEG). Patients who maintained seizure freedom for two consecutive weekly visits were entered into the Maintenance Phase (n=30). Diary, clinic HV, and HV/EEG data were supplemented with 24-h ambulatory EEG at baseline and the ends of the Escalation and Maintenance Phases. Health outcome assessments were completed at screening and at the end of the Maintenance Phase.
  
  
  RESULTS
  By the end of the Escalation Phase, seizure-free rates (responders) were 59% by seizure diary (n=51), 56% by HV/EEG (n=54) (primary endpoint), and 49% by 24-h ambulatory EEG (n=49). During the Maintenance Phase, 89% (week 24) and 86% (week 32) remained seizure free by diary (n=28), 78% by clinic HV (n=27), and 81% by 24-h ambulatory EEG (n=26). Seizure freedom was first observed beginning at the fifth week of the Escalation Phase. The most frequent adverse events were headache and cough. Health outcome scores were either improved or unchanged at the end of the Maintenance Phase.
  
  
  CONCLUSIONS
  Lamotrigine monotherapy results in complete seizure freedom in a substantial number of children with typical absence seizures. Lamotrigine was well tolerated in this study.
authors.affiliation: Neuroscience Center at Dartmouth, Dartmouth Medical School, Lebanon, NH, USA. Gregory.L.Holmes@dartmouth.edu
authors.forename: Gregory L
authors.initials: GL
authors.lastname: Holmes
authors.forename: L Matthew
authors.initials: LM
authors.lastname: Frank
authors.forename: Raj D
authors.initials: RD
authors.lastname: Sheth
authors.forename: Bryan
authors.initials: B
authors.lastname: Philbrook
authors.forename: John D
authors.initials: JD
authors.lastname: Wooten
authors.forename: Alain
authors.initials: A
authors.lastname: Vuong
authors.forename: Susan
authors.initials: S
authors.lastname: Kerls
authors.forename: Anne E
authors.initials: AE
authors.lastname: Hammer
authors.forename: John
authors.initials: J
authors.lastname: Messenheimer
mesh_terms: D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004569:Electroencephalography / Q000187:drug effects; D004832:Epilepsy, Absence / Q000188:drug therapy*; D005260:Female; D006261:Headache / Q000209:etiology; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D008499:Medical Records; D018670:Monitoring, Ambulatory; D016896:Treatment Outcome; D014227:Triazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D014227:Triazines; D000077213:Lamotrigine
references.citation: Epilepsia. 1999 Jul;40(7):985-91
references.pmid: 10403224
references.citation: J Genet Psychol. 1994 Dec;155(4):487-92
references.pmid: 7852984
references.citation: J Child Neurol. 2002 Apr;17(4):278-85
references.pmid: 12088084
references.citation: Epilepsia. 2006 Feb;47(2):318-22
references.pmid: 16499755
references.citation: Arch Gen Psychiatry. 1987 Sep;44(9):821-4
references.pmid: 3632256
references.citation: Acta Neurol Scand. 1995 Mar;91(3):200-2
references.pmid: 7793236
references.citation: Can J Neurol Sci. 1998 Nov;25(4):S14-8
references.pmid: 9827240
references.citation: Can J Neurol Sci. 2003 Aug;30(3):184-8
references.pmid: 12945939
references.citation: Neurology. 1996 Oct;47(4):912-8
references.pmid: 8857718
references.citation: Seizure. 2005 Mar;14(2):117-22
references.pmid: 15694565
references.citation: Arch Neurol. 1996 Sep;53(9):929-32
references.pmid: 8815859
references.citation: Epilepsia. 2005 Nov;46(11):1796-801
references.pmid: 16302860
references.citation: Eur J Paediatr Neurol. 2001;5(1):37-40
references.pmid: 11277363
references.citation: Expert Rev Neurother. 2006 Jun;6(6):855-62
references.pmid: 16784409
references.citation: Neurology. 1974 Jul;24(7):659-65
references.pmid: 4858089
references.citation: Brain Dev. 1999 Jul;21(5):303-6
references.pmid: 10413016
references.citation: Brain. 1975 Sep;98(3):427-40
references.pmid: 1182486
references.citation: Arch Neurol. 1983 Aug;40(8):469-72
references.pmid: 6409062
references.citation: Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003032
references.pmid: 16235312
references.citation: Electroencephalogr Clin Neurophysiol. 1973 Mar;34(3):239-45
references.pmid: 4129611
references.citation: Arch Pediatr Adolesc Med. 1997 Feb;151(2):152-8
references.pmid: 9041870
references.citation: Paediatr Drugs. 2001;3(5):379-403
references.pmid: 11393330
references.citation: Brain Dev. 2004 Jan;26(1):26-9
references.pmid: 14729411
references.citation: Clin Evid. 2005 Jun;(13):221-6
references.pmid: 16135261
references.citation: Eur J Paediatr Neurol. 2006 May;10(3):135-41
references.pmid: 16759890
references.citation: Epilepsia. 2004 Sep;45(9):1049-53
references.pmid: 15329068
references.citation: Arch Gen Psychiatry. 1983 Nov;40(11):1228-31
references.pmid: 6639293
references.citation: Lancet. 2007 Mar 24;369(9566):1016-26
references.pmid: 17382828
references.citation: Neurology. 1981 Sep;31(9):1175-7
references.pmid: 6791054
references.citation: Epilepsia. 1999 Jul;40(7):973-9
references.pmid: 10403222
references.citation: J Child Neurol. 2006 Sep;21(9):766-8
references.pmid: 16970883